AAV2 GDNF

Drug Profile

AAV2 GDNF

Alternative Names: AAV2-GDNF; AMT-140

Latest Information Update: 05 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator uniQure
  • Developer Lund University; National Institute of Neurological Disorders and Stroke; uniQure; University of California at San Francisco
  • Class Antiparkinsonians; Gene therapies; Neuroprotectants
  • Mechanism of Action Gene transference; Glial cell line-derived neurotrophic factor expression stimulants; Neuron stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Parkinson's disease

Highest Development Phases

  • Phase I/II Parkinson's disease

Most Recent Events

  • 28 Aug 2017 Protein Sciences Corporation has been acquired by Sanofi
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Parkinson's-disease in Sweden (Intracerebral, Infusion)
  • 30 Sep 2014 The University of California San Francisco and the National Institute of Neurological Disorders and Stroke complete treatment of patients in the first dose cohort in the phase I trial in Parkinson's disease
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top